Live Breaking News & Updates on Department of neurology neurological sciences

Stay updated with breaking news from Department of neurology neurological sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Genetic Testing Warranted in Epilepsy of Unknown Origin

Benefits of genetic testing in adults with unexplained epilepsy include enrollment in a clinical trial of a relevant gene therapy, connection to families with a similar diagnosis, and peace of mind. ....

United-states , Massachusetts , Stanford-university , California , Stanford , Boston , American , Yi-li , American-epilepsy-society , National-society-of-genetic-counselors , Epilepsy-genetics-program , Department-of-neurology-neurological-sciences

More Evidence In Utero Exposure to Antiseizure Meds Safe for Kids

A new study provides more reassurance that in utero exposure to antiseizure medications are safe and do not have a negative effect on children s cognition. ....

Stanford-university , California , United-states , Paris , France-general , France , Palo-alto , American , Kimfordj-meador , Department-of-neurology-neurological-sciences , American-epilepsy-society

Immunic (IMUX) Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium

Immunic (IMUX) Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Germany , New-york , United-states , Hohendorf , Sachsen , Hella-kohlhof , Lawrence-steinman , Steinmanl-epstein-barr , Heinz-wiendl , Larry-steinman , Fred-lublin , Daniel-vitt

EQS-News: Immunic, Inc.: Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting ....

Germany , New-york , United-states , Hohendorf , Sachsen , Russia , Ukraine , Paula-schwartz , Lawrence-steinman , Edna-kaplan , Hella-kohlhof , Steinmanl-epstein-barr

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused. ....

Germany , New-york , United-states , Hohendorf , Sachsen , Russia , Ukraine , Paula-schwartz , Lawrence-steinman , Edna-kaplan , Hella-kohlhof , Steinmanl-epstein-barr